Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Cannabichromene (CBC) is a phytocannabinoid commonly found in cannabis, yet its acute post-dose pharmacokinetics (PK) have not been examined in humans. This is a secondary data analysis from a trial investigating Spectrum Yellow oil, an oral cannabis product used for medical purposes that contained 20 mg cannabidiol (CBD), 0.9 mg Δ Participants (N 43) were randomized to one of 5 groups 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily or placebo. Study medication was administered every 12 h for 7 days. Plasma CBC concentrations were analyzed by a validated two-dimensional high-performance liquid chromatography-tandem mass spectrometry assay. After a single dose and after the final dose, the C CBC may have preferential absorption over CBD and THC when administered together. Australian New Zealand Clinical Trials Registry ACTRN12619001450101, registered 18 October 2019.